Janux Therapeutics第一季度每股收益$（0.30）击败$（0.33）估计，销售额125万美元击败76万美元估计

Janux Therapeutics (NASDAQ: JANX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 28.57 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $1.25 million which beat the analyst consensus estimate of $760.00 thousand by 64.74 percent. This is a 38.87 percent decrease over sales of $2.05 million the same period last year.